Is there an AI bubble? No, but some tech companies show signs

The AI sector is not in a bubble market, but the prices of some individual AI companies behave with the price variability and exuberance characteristic of a bubble, according to new Cornell research.

Alum shares wisdom from career journey

Jason Marvin, Ph.D. ’22, spoke about his journey from biomedical engineering doctorate to his current position during the Summer Success Symposium alumni keynote on Aug. 18.

Around Cornell

Existing drug could treat invasive canine oral tumors

A new diagnostic tool distinguishes between two similar canine oral cancers, opening the door for a promising FDA-approved treatment.

A new ingredient for quantum computing: krypton gas

Researchers developed a method that uses krypton gas to slash the deposition temperature of the corrosion-resistant metal tantalum, resulting in thin films that have substantially higher electronic conductivity.

Distinct neurons drive mice’s social sounds and squeaks

The discovery is a step toward understanding how the brain is organized to control vocalization in mammals, including humans.

A better pill to swallow: Nanofiber film delivers ultrafast pain relief

Researchers developed an ultrafast-dissolving nanofiber film that can deliver a cocktail of three drugs so quickly and effectively, 90% of the formulation is released in less than two seconds. 

Engineered microbe speeds CO2 capture, recovers critical metals

A genetically engineered bacterium can rapidly break down one of Earth’s most abundant minerals, opening a promising new pathway for removing CO2 from the atmosphere and recovering critical elements, according to new Cornell research.

Alum’s company creates tech for pain-free tattoos

A company founded by a Cornell doctoral alum is using microneedle technology to create a pain-free tattoo experience.

Around Cornell

Attacking cancer-enabling proteins where they live

Using a photochemically driven labeling technique, a Cornell-led research group has devised a way to capture cancer-specific protein-to-protein interactions, which could spawn targeted therapies for prostate and other forms of the disease.